Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study

By M. Bogenschutz, Alyssa A. Forcehimes, Jessica A Pommy, C. Wilcox, P. Barbosa, R. Strassman. Journal of Psychopharmacology, 2015

1,033 citations recorded by the source corpus.

Subfields: Clinical Psychology, Social Psychology, Toxicology

View Paper: https://www.semanticscholar.org/paper/b7d67ab77a7ae8786fcfa5a4d8bbec12f6e137ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Psychology

In Social Psychology

In Toxicology

Citations in the corpus

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. (2016, background): “19 Signiﬁ cantly decreased anxiety and depression scores were observed 3 and 6 months after a single dose of psilocybin in patients with anxiety related to end-stage cancer, 15 and improve ments in wellbeing lasting for more than 1 year were observed in healthy individuals given a single dose of…”
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial (2018, background): “Prior studies suggest that elements of the psychedelic experience, such as experiences of mystical-type, account for the therapeutic benefit (Bogenschutz et al., 2015; Garcia-Romeu et al., 2015; Majić et al., 2015; Griffiths et al., 2016; Ross et al., 2016).”
Serotonin and brain function: a tale of two receptors (2017, background): “Moreover, an increasing number of studies are reporting enduring positive mental health outcomes (Bogenschutz et al., 2015; Bouso et al., 2012; Gasser et al., 2014; Grob et al., 2011; Hendricks et al., 2015b; Osorio Fde et al., 2015) and psychological well-being (Carhart-Harris et al., 2016c;…”
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial (2016, background): “…corroborated by recent open-label trials using psilocybin-assisted psychotherapy to treat tobacco addiction (Garcia-Romeu et al., 2014; Johnson et al., 2014) and alcoholism (Bogenschutz et al., 2015) showing significant correlations between the mystical experience and improved clinical outcomes.”
Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression (2017, neutral): “Since 2006, there have been nine separate studies conducted by eight independent research teams on the clinical utility of psychedelics (Bogenschutz et al., 2015; Carhart-Harris, Bolstridge, et al., 2016; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011; Johnson, Garcia-Romeu, &…”
Psychedelics (2016, background): “These investigators carried out an open-label proof-of-concept trial of psilocybin treatment in a sample of 10 volunteers with a DSM-IV diagnosis of alcohol dependence (Bogenschutz et al., 2014).”
REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics (2019, background): “Evidence from a series of recent small-scale studies (Moreno et al., 2006; Grob et al., 2011; Gasser et al., 2014; Bogenschutz et al., 2015; Osório Fde et al., 2015; Carhart-Harris et al., 2016a, 2018a; Griffiths et al., 2016; Ross et al., 2016; Palhano-Fontes et al., 2019), in addition to…”
The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future (2017, background): “…clinical development of psychedelics, RLC-H sees it as a potentially exploitable component—especially as it has been shown to be predictive of long-term clinical outcomes (eg, in Johnson et al, 2014; Bogenschutz et al, 2015; Griffiths et al, 2016; Ross et al, 2016; Carhart-Harris et al, 2016a,b).”
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression (2018, background): “This is important, not least because they are proving to be important determinants of treatment success in psychedelic therapy (Richards et al., 1977; Bogenschutz et al., 2015; Griffiths et al., 2016; Johnson et al., 2016; Ross et al., 2016).”
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up (2017, background): “Psilocybin has shown promise in the treatment of obsessive compulsive disorder (Moreno et al. 2006), alcohol (Bogenschutz et al. 2015) and tobacco addiction (Johnson et al. 2014) and anxiety related to terminal diagnoses (Griffiths et al. 2016; Ross et al. 2016; Grob et al. 2011).”